Chuwei Yu

Chuwei Yu

Auto-generated profile, based on publicly available information

Chuwei Yu

Lingang Laboratory, Shanghai, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in Cancer Research
Verified
Journal Article
Open access
ZLZiwei Luo
Ziwei Luo
CLChencen Lin
Chencen Lin
CYChuwei Yu
Chuwei Yu
CYChangxian Yuan
Changxian Yuan
WWWenyong Wu
Wenyong Wu
CXChengying Xie
Chengying Xie
Son of sevenless homolog 1 (SOS1) is an essential guanine nucleotide exchange factor for RAS that also plays a critical role in the activation of the small GTPase RAC mediated by BCR–ABL in leukemogenesis. Despite this, small-molecule inhibitors targeting SOS1 have shown limited efficacy in clinical trials for KRAS-mutant cancers, and their potential as a therapeutic approach for chronic myeloid leukemia (CML) remains largely unexplored. In this study, we developed a potent SOS1 proteolysis targeting chimera (PROTAC) SIAIS562055, which was designed by connecting a CRBN ligand to an analog of the SOS1 inhibitor BI-3406. SIAIS562055 exhibited sustained degradation of SOS1 and inhibition of downstream ERK pathways, resulting in superior antiproliferative activity compared with small-molecule inhibitors. SIAIS562055 also potentiated the activity of both KRAS inhibitors in KRAS-mutant cancers and ABL inhibitors in BCR–ABL–positive CML. In KRAS-mutant xenografts, SIAIS562055 displayed promising antitumor potency as a monotherapy and enhanced ERK inhibition and tumor regression when combined with KRAS inhibitors, overcoming acquired resistance. In CML cells, SIAIS562055 promoted the active uptake of BCR–ABL inhibitors by upregulating the carnitine/organic cation transporter SLC22A4. SIAIS562055 and BCR–ABL inhibitors synergistically enhanced inhibition of ABL phosphorylation and downstream signaling, demonstrating robust antitumor activities in both mouse xenografts and primary samples from patients with CML. In summary, this study suggests that PROTAC-mediated SOS1 degradation represents an effective therapeutic strategy for treating not only KRAS-mutant cancers but also BCR–ABL–harboring leukemia. Significance: The PROTAC SIAIS562055 sustainably degrades SOS1 and inhibits downstream ERK signaling, showing strong antiproliferative activity and synergistic effects with KRAS inhibitors in KRAS-mutant cancers and BCR–ABL inhibitors in chronic myeloid leukemia.

17 June 2026
Verified
Other
Open access
ZLZiwei Luo
Ziwei Luo
CLChencen Lin
Chencen Lin
CYChuwei Yu
Chuwei Yu
CYChangxian Yuan
Changxian Yuan
WWWenyong Wu
Wenyong Wu
CXChengying Xie
Chengying Xie
Son of sevenless homolog 1 (SOS1) is an essential guanine nucleotide exchange factor for RAS that also plays a critical role in the activation of the small GTPase RAC mediated by BCR–ABL in leukemogenesis. Despite this, small-molecule inhibitors targeting SOS1 have shown limited efficacy in clinical trials for KRAS-mutant cancers, and their potential as a therapeutic approach for chronic myeloid leukemia (CML) remains largely unexplored. In this study, we developed a potent SOS1 proteolysis targeting chimera (PROTAC) SIAIS562055, which was designed by connecting a CRBN ligand to an analog of the SOS1 inhibitor BI-3406. SIAIS562055 exhibited sustained degradation of SOS1 and inhibition of downstream ERK pathways, resulting in superior antiproliferative activity compared with small-molecule inhibitors. SIAIS562055 also potentiated the activity of both KRAS inhibitors in KRAS-mutant cancers and ABL inhibitors in BCR–ABL–positive CML. In KRAS-mutant xenografts, SIAIS562055 displayed promising antitumor potency as a monotherapy and enhanced ERK inhibition and tumor regression when combined with KRAS inhibitors, overcoming acquired resistance. In CML cells, SIAIS562055 promoted the active uptake of BCR–ABL inhibitors by upregulating the carnitine/organic cation transporter SLC22A4. SIAIS562055 and BCR–ABL inhibitors synergistically enhanced inhibition of ABL phosphorylation and downstream signaling, demonstrating robust antitumor activities in both mouse xenografts and primary samples from patients with CML. In summary, this study suggests that PROTAC-mediated SOS1 degradation represents an effective therapeutic strategy for treating not only KRAS-mutant cancers but also BCR–ABL–harboring leukemia.Significance:The PROTAC SIAIS562055 sustainably degrades SOS1 and inhibits downstream ERK signaling, showing strong antiproliferative activity and synergistic effects with KRAS inhibitors in KRAS-mutant cancers and BCR–ABL inhibitors in chronic myeloid leukemia.

17 June 2026
Verified
Other
Open access
ZLZiwei Luo
Ziwei Luo
CLChencen Lin
Chencen Lin
CYChuwei Yu
Chuwei Yu
CYChangxian Yuan
Changxian Yuan
WWWenyong Wu
Wenyong Wu
CXChengying Xie
Chengying Xie
SIAIS562055 combined with KRAS inhibitors overcomes drug resistance. A, Western blot analysis of SOS1 in Ba/F3 cells transformed with or without KRAS mutation after treatment with SIAIS562055 (1,000 nmol/L) or BI-3406 (1,000 nmol/L) for 24 hours. B, Antiproliferative effects of SIAIS562055 on Ba/F3 cells transformed with or without KRAS mutations for 72 hours. Histogram shows the IC50 values of compounds in two-dimensional (2D) cultured cells. C, Cell proliferative inhibition of MIA PaCa-2 and MIA PaCa-2/R cells treated with AMG510 and MRTX849 for 72 hours. Histogram shows the IC50 values of compounds and resistance factors (RF) in 2D cultured cells. D, Western blot analysis of SOS1 by SIAIS562055 in MIA PaCa-2 and MIA PaCa-2/R cells for 72 hours. MIA PaCa-2/R xenograft-bearing mice received vehicle, SIAIS562055, and MRTX849, alone or in combination, then, the relative tumor volumes (E) and mouse body weights (F) were tested. qd, once a day. G, Western blot analysis of SOS1, pERK, and cleaved caspase-3 in MIA PaCa-2/R xenograft tumor tissues. Data about relative tumor volumes and body weights are presented as mean ± SEM, n = 5, whereas other statistical data are presented as mean ± SD, n = 3. **, P < 0.01; ***, P < 0.001.

17 June 2026
Verified
Other
Open access
ZLZiwei Luo
Ziwei Luo
CLChencen Lin
Chencen Lin
CYChuwei Yu
Chuwei Yu
CYChangxian Yuan
Changxian Yuan
WWWenyong Wu
Wenyong Wu
CXChengying Xie
Chengying Xie
SIAIS562055 inhibits the proliferation of CML cells in vitro. A, Western blot analysis of SOS1 in K562 cells treated with SIAIS562055 (1,000 nmol/L), SIAIS562092 (1,000 nmol/L), or BI-3406 (1,000 nmol/L) for 24 hours, with or without the pretreatment of MG132 (1,000 nmol/L) for 1 hour. B, Western blot analysis of SOS1, pERK, GSPT1, and IKZF3 in K562 cells treated with SIAIS562055, SIAIS562092, or BI-3406 for 24 hours. C, Western blot analysis of SOS1 and pERK in K562 cells treated with a time gradient of SIAIS562055 or SIAIS562092. Histogram shows the relative SOS1 levels. D, Western blot analysis of SOS1 and pERK in K562 cells treated with SIAIS562055 (1,000 nmol/L), SIAIS562092 (1,000 nmol/L), or BI-3406 (1,000 nmol/L) for 12 hours, followed by wash-out and incubation with fresh media for another 0, 24, 48, and 72 hours. Line chart shows the relative pERK levels. E, Western blot analysis of SOS1 and pERK in K562 and KU812 cells treated with SIAIS562055 for 24 hours in a concentration gradient. F, Antiproliferative effects in K562 and KU812 cells after treatment with SIAIS562055 for 72 hours. Line charts show the IC50 values of two-dimensional culture. Data are shown as mean ± SD, n = 3. **, P < 0.01; ***, P < 0.001; ns, not significant.

2 January 2025
Verified
Other
Open access
ZLZiwei Luo
Ziwei Luo
CLChencen Lin
Chencen Lin
CYChuwei Yu
Chuwei Yu
CYChangxian Yuan
Changxian Yuan
WWWenyong Wu
Wenyong Wu
CXChengying Xie
Chengying Xie
SIAIS562055 selectively degrades SOS1. A, Chemical structure of SIAIS562055 (562055 for short). B, Ternary complex of SIAIS562055, E3 ligase CRBN, and SOS1 determined by computer simulation. C, Visual inspection and interaction fingerprint analysis of the ternary complex. D, SPR assay was used to test the binding affinity of SIAIS562055 with SOS1. E, HTRF assay of the SOS1 and KRAS interaction after treatment with SIAIS562055 or BI-3406 at different concentrations. Data are shown as mean ± SD, n = 3. F, Effects of SOS1 by SIAIS562055 (1,000 nmol/L), SIAIS562092 (562092 for short; 1,000 nmol/L), or BI-3406 (1,000 nmol/L) for 24 hours with or without pretreatment of MG132 (1,000 nmol/L) for 1 hour in NCI-H358 and GP2d cells. G, Western blot analysis of SOS1, pERK, GSPT1, and IKZF1/3 in NCI-H358 cells treated with SIAIS562055, SIAIS562092, or BI-3406 for 24 hours. Data are representative of three independent replicates.

2 January 2025
Verified
Other
Open access
ZLZiwei Luo
Ziwei Luo
CLChencen Lin
Chencen Lin
CYChuwei Yu
Chuwei Yu
CYChangxian Yuan
Changxian Yuan
WWWenyong Wu
Wenyong Wu
CXChengying Xie
Chengying Xie
Combination of SIAIS562055 and TKIs synergistically inhibits the growth of CML xenografts in vivo and enhances cell death in primary samples from patients with CML. A–D, K562-xenografted mice received vehicle, SIAIS562055 (30 mg/kg/day), imatinib (100 mg/kg/day), or their combination; then, relative tumor volumes (A), tumor weights (B), photo of tumors (C), and mice body weights (D) were determined at indicated times. Data are presented as mean ± SEM, n = 5. E, Western blot analysis of SOS1, pERK, and pSTAT5 in K562 xenograft tumors after treatment with vehicle, SIAIS562055, imatinib, or their combination. Data are shown as mean ± SEM, n = 5. F, Cell viability of three primary BCR–ABL+ samples from patients with CML treated with varying doses of SIAIS562055 or imatinib, alone or in combination, for 72 hours was assessed by CellTiter-Glo assay. Data are presented as mean ± SD, n = 3. G, Western blot analysis of the indicated proteins in primary samples from patients with CML under 24-hour exposure to SIAIS562055 or imatinib, alone or in combination. Statistical significance was assessed using two-tailed unpaired Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. qd, once a day.